A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Norikazu MasudaShoichiro OhtaniToshimi TakanoKenichi InoueEiji SuzukiRikiya NakamuraHiroko BandoYoshinori ItoKazushige IshidaTakashi YamanakaKatsumasa KuroiHiroyuki YasojimaHiroi KasaiTsuyoshi TakasukaTakaki SakuraiTatsuki R KataokaSatoshi MoritaShinji OhnoMasakazu ToiPublished in: Breast cancer research and treatment (2020)
In the neoadjuvant setting, the pCR rate with the standard TCbHP → T-DM1+P regimen was numerically better than the TCbHP regimen alone and significantly better in patients with ER+. Personalization of the T-DM1+P regimen could serve as a reasonable approach to minimize toxicity while maintaining efficacy. Trial registration ID: UMIN-CTR: UMIN000014649.
Keyphrases
- metastatic breast cancer
- epidermal growth factor receptor
- locally advanced
- rectal cancer
- lymph node
- glycemic control
- phase iii
- phase ii study
- tyrosine kinase
- study protocol
- open label
- oxidative stress
- squamous cell carcinoma
- type diabetes
- radiation therapy
- randomized controlled trial
- positive breast cancer
- breast cancer cells
- skeletal muscle
- estrogen receptor
- double blind
- endoplasmic reticulum